My impression was that antibodies targeted against amyloid failed in clinical trials largely because they were tested in patients already with enough amyloid burden such that neuronal toxicity had already been achieved.
Do you expect that your treatment would work better than these antibodies, in a comparable test subject population?
MPRUC1 karma
My impression was that antibodies targeted against amyloid failed in clinical trials largely because they were tested in patients already with enough amyloid burden such that neuronal toxicity had already been achieved.
Do you expect that your treatment would work better than these antibodies, in a comparable test subject population?
View HistoryShare Link